Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation – A systematic review of randomized trials, observational studies and case reports

Background: The prevalence of cancer-related pain and residual pain in cancer survivors is high. Opioids serve as the gold standard for treating moderate to severe cancer pain. The evaluation of the effectiveness of opioids in chronic non-cancer pain has shown a lack of effectiveness, or rather weak evidence for some of the drugs. In contrast, in cancer pain, opioids are expected to be very effective. Due to the nature of the disease, there is evidence of a paucity of randomized trials investigating opioid effectiveness in cancer pain on a long-term basis. Consequently, the effectiveness of opioids in managing cancer-related pain warrants further evidence-based review beyond randomized trials, including observational studies and case reports. Methods: The comprehensive literature search was conducted for the period 1996 through June 2010. Databases for the search included PubMed, EMBASE, Cochrane Reviews, and clinicaltrails.gov, along with reviews and cross references. Methodologic quality assessment of the observational studies managing chronic cancer pain with opioids was conducted utilizing the Agency for Healthcare Research and Quality (AHRQ) criteria for observational studies. Analysis of evidence included 5 levels of evidence developed by the United States Preventive Services Task Force (USPSTF) ranging from Level I to III with 3 subcategories in Level II. Grading recommendations were based on Guyatt et al’s recommendations with 6 levels: 3 in the strong category and 3 in the weak category. Results: This evaluation is of 18 manuscripts considered for inclusion; 7 manuscripts met the inclusion criteria based on AHRQ quality assessment. Level of evidence for opioid therapy in cancer pain was Level II-3, and recommendations were 1C/strong recommendation based on observational studies, which could change based on future evidence. Conclusion: This systematic review of observational studies indicates Level II3 evidence for effectiveness of opioids in cancer pain therapy, with 1C/strong recommendation based on observational studies, which could change based on future evidence. Key words: Chronic pain, cancer pain, non-cancer pain, randomized trials, observational studies, case reports, opioids, effectiveness

Download Full-text

COVID-19 in Patients with Solid Organ Transplantation: A Systematic Review

Transplantology ◽

10.3390/transplantology1010001 ◽

2020 ◽

Vol 1 (1) ◽

pp. 1-15 ◽

Cited By ~ 7

Author(s):

René Hage ◽

Carolin Steinack ◽

Christian Benden ◽

Macé M. Schuurmans

Keyword(s):

Systematic Review ◽

Social Life ◽

Case Reports ◽

Solid Organ Transplantation ◽

Organ Transplant ◽

Case Series ◽

Google Scholar ◽

Current Evidence ◽

Solid Organ ◽

Increased Risk

The novel coronavirus, SARS-CoV-2, is causing a pandemic of unknown precedent, with huge healthcare challenges and worldwide disruptions to economic and social life. Lung transplant recipients and other solid organ transplant (SOT) recipients are immunosuppressed, and therefore are generally considered at an increased risk for severe infections. Given the current gap in knowledge and evidence regarding the best management of these patients, we conducted a systematic review of studies on SARS-CoV-2 infections and Coronavirus Disease 2019 (COVID-19) in SOT recipients, to evaluate the association between immunosuppression in these patients, SARS-CoV-2 infection and COVID-19 outcomes. The focus was the severity of the disease, the need for mechanical ventilation and intensive care unit (ICU) admissions, and rate of death. The literature search was conducted repeatedly between 16 March and 8 April 2020. We searched original papers, observational studies, case reports, and meta-analyses published between 2019 and 2020 using two databases (PubMed, Google Scholar) with the search terms: [transplant OR immunosuppression] AND [COVID-19 OR SARS-CoV-2]. Further inclusion criteria were publications in English, French, German and Italian, and reference to humans. We also searched the reference lists of the studies encountered. From an initial search of PubMed and Google Scholar, 19 potential articles were retrieved, of which 14 were excluded after full-text screening (not being case reports or case series), leaving 5 studies for inclusion. No further studies were identified from the bibliographies of retrieved articles. Based on the limited research, no firm conclusions can be made concerning SOT recipients, but the current evidence suggests that immunosuppression is most likely associated with a better outcome of SARS-CoV-2 infection and COVID-19 because it prevents hyperinflammation (cytokine storm) in this particular population. There is a need for further research that would allow results to be adjusted for other factors potentially impacting COVID-19 severity and outcome.

Download Full-text

Immune-Mediated Cytopenia following Bone Marrow Transplantation Case Reports and Review of the Literature

Medicine ◽

10.1097/00005792-199203000-00002 ◽

1992 ◽

Vol 71 (2) ◽

pp. 73-83 ◽

Cited By ~ 31

Author(s):

Thomas R. Klumpp ◽

Caroline C. Block ◽

Michael A. Caligiuri ◽

Susan N. Rabinowe ◽

Robert J. Soiffer ◽

...

Keyword(s):

Bone Marrow ◽

Bone Marrow Transplantation ◽

Marrow Transplantation ◽

Case Reports ◽

Review Of The Literature ◽

Immune Mediated

Download Full-text

IMMUNOSUPRESSION-FREE PROTOCOL IN SOLID ORGAN TRANSPLANTATION YEARS FOLLOWING BONE-MARROW TRANSPLANTATION

Transplantation Journal ◽

10.1097/01.tp.0000330697.40033.7e ◽

2008 ◽

Vol 86 (Supplement) ◽

pp. 612

Author(s):

E Mor ◽

N Bar-Nathan ◽

Y Frishberg ◽

R Becker-Cohen ◽

T Klein ◽

...

Keyword(s):

Bone Marrow ◽

Bone Marrow Transplantation ◽

Organ Transplantation ◽

Marrow Transplantation ◽

Solid Organ Transplantation ◽

Solid Organ

Download Full-text

The toxic effects of chloroquine and hydroxychloroquine on skeletal muscle: a systematic review and meta-analysis

Scientific Reports ◽

10.1038/s41598-021-86079-4 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Claudia Cristina Biguetti ◽

Joel Ferreira Santiago Junior ◽

Matthew William Fiedler ◽

Mauro Toledo Marrelli ◽

Marco Brotto

Keyword(s):

Systematic Review ◽

Quantitative Analysis ◽

Qualitative Analysis ◽

Observational Studies ◽

Skeletal Muscles ◽

Case Reports ◽

Meta Analysis ◽

Toxic Effects ◽

Drug Induced ◽

Qualitative And Quantitative

AbstractThe aim of this systematic review was to perform qualitative and quantitative analysis on the toxic effects of chloroquine (CQ) and hydroxychloroquine (HCQ) on skeletal muscles. We designed the study according to PRISMA guidelines. Studies for qualitative and quantitative analyses were selected according to the following inclusion criteria: English language; size of sample (> 5 patients), adult (> age of 18) patients, treated with CQ/HCQ for inflammatory diseases, and presenting and not presenting with toxic effects on skeletal muscles. We collected data published from 1990 to April 2020 using PubMed, Cochrane Library, EMBASE, and SciELO. Risk of bias for observational studies was assessed regarding the ROBIN-I scale. Studies with less than five patients (case reports) were selected for an additional qualitative analysis. We used the software Comprehensive Meta-Analysis at the confidence level of 0.05. We identified 23 studies for qualitative analysis (17 case-reports), and five studies were eligible for quantitative analysis. From case reports, 21 patients presented muscle weakness and confirmatory biopsy for CQ/HCQ induced myopathy. From observational studies, 37 patients out of 1,367 patients from five studies presented muscle weakness related to the use of CQ/HCQ, and 252 patients presented elevated levels of muscle enzymes (aldolase, creatine phosphokinase, and lactate dehydrogenase). Four studies presented data on 34 patients with confirmatory biopsy for drug-induced myopathy. No study presented randomized samples. The chronic use of CQ/HCQ may be a risk for drug-induced myopathy. There is substantiated need for proper randomized trials and controlled prospective studies needed to assess the clinical and subclinical stages of CQ/HCQ -induced muscle myopathy.

Download Full-text